e-learning
resources
ERJ
2006
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Thalidomide reduces IL-18, IL-8 and TNF-α release from alveolar macrophages in interstitial lung disease
Ye Q., Chen B., Tong Z., Nakamura S., Sarria R., Costabel U., Guzman J.
Source:
Eur Respir J 2006 Oct 01;28(4):824-831
Journal Issue:
October
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Ye Q., Chen B., Tong Z., Nakamura S., Sarria R., Costabel U., Guzman J.. Thalidomide reduces IL-18, IL-8 and TNF-α release from alveolar macrophages in interstitial lung disease. Eur Respir J 2006 Oct 01;28(4):824-831
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ANCA associated vasculitis and lung disease
Panel discussion on genetics in pulmonary fibrosis
The new challenge of CTD-ILD: from basic science to clinical setting
Related content which might interest you:
Effect of nintedanib on the release of angiogenic/angiostatic cytokines by alveolar macrophages (AMs) in interstitial lung diseases (ILD)
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015
N-acetylcysteine reduces tumor necrosis factor-α release by alveolar macrophages of interstitial lung disease
in vitro
Source: Annual Congress 2007 - Considerations in the therapeutic approach of interstitial lung disease: oxidative stress and inflammation
Year: 2007
M2 polarized alveolar macrophages in pulmonary fibrosis
Source: Annual Congress 2005 - Pulmonary hypertension and fibrosis: novel mechanisms
Year: 2005
Alveolar macrophage oxidative and pro-inflammatory cytokine activity in lung sarcoidosis
Source: Eur Respir J 2005; 26: Suppl. 49, 332s
Year: 2005
Raised interleukin-17 is immunolocalised to neutrophils in cystic fibrosis lung disease
Source: Eur Respir J 2011; 37: 1378-1385
Year: 2011
HGF and IL-6 in BAL fluid of interstitial lung diseases: effect on human lung fibroblasts
Source: Annual Congress 2008 - Role of bronchoalveolar lavage in studying the pathophysiology of interstitial lung disease
Year: 2008
Azithromycin increases phagocytosis of apoptotic bronchial epithelial cells by alveolar macrophages
Source: Eur Respir J 2006; 28: 486-495
Year: 2006
β-Adrenoceptor stimulation and neutrophil accumulation in mouse airways
Source: Eur Respir J 2004; 24: 231-237
Year: 2004
The production of IL-18, IL-12 and TNF-alpha by alveolar macrophages in sarcoidosis and hypersensitivity pneumonitis
Source: Eur Respir J 2003; 22: Suppl. 45, 177s
Year: 2003
Increased production of caspase-1 by alveolar macrophages in patients with pulmonary sarcoidosis
Source: Eur Respir J 2002; 20: Suppl. 38, 585s
Year: 2002
A role of GM-CSF in the accumulation of neutrophils in the airways caused by IL-17 and TNF-α
Source: Eur Respir J 2003; 21: 387-393
Year: 2003
Relationship between IL-8, IL-10, MMP-9 and morphological findings in BAL fluid of patients with interstitial lung diseases
Source: Eur Respir J 2003; 22: Suppl. 45, 225s
Year: 2003
Oxidative burst in lipopolysaccharide-activated human alveolar macrophages is inhibited by interleukin-9
Source: Eur Respir J 2002; 20: 1198-1205
Year: 2002
The effect of pentoxifylline on IL-12 and IL-18 release by alveolar macrophages in sarcoidosis and hypersensitivity pneumonitis versus idiopathic pulmonary fibrosis
Source: Eur Respir J 2003; 22: Suppl. 45, 377s
Year: 2003
Alveolar macrophages and CC chemokines are increased in children with cystic fibrosis
Source: Eur Respir J 2009; 34: 655
Year: 2009
CTGF and TNFa expression in alveolar macrophages of patients with idiopathic pulmonary fibrosis before and after treatment with azathioprine and interferon-g
Source: Annual Congress 2009 - Idiopathic pulmonary fibrosis: concepts and mechanisms
Year: 2009
Effect of pirfenidone (PFD) on cytokine/chemokine release from alveolar macrophages (AMs) in interstitial lung diseases (ILD): Preliminary results
Source: Annual Congress 2013 –Diffuse pulmonary fibrosis
Year: 2013
Resveratrol impairs the release of steroid-resistant cytokines from bacterial endotoxin-exposed alveolar macrophages (AM) in COPD
Source: Annual Congress 2011 - Experimental modulation of airway inflammation
Year: 2011
α1-Antitrypsin inhalation reduces airway inflammation in cystic fibrosis patients
Source: Eur Respir J 2007; 29: 240-250
Year: 2007
Eosinophil cationic protein stimulates TGF-β
1
release by human lung fibroblasts
Source: Annual Congress 2005 - Inflammation and remodelling in allergy and asthma
Year: 2005
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept